NASDAQ · MPLT
MapLight Therapeutics, Inc.
$7.72-$0.26 (-3.26%)
MapLight Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.91% below the high.
Loading market information…
NASDAQ · TXMD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
TherapeuticsMD, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
TherapeuticsMD, Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$6.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow TherapeuticsMD, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 27, 2025 |
| $0.02-45.38% vs estimate |
| $667.00K-71.0% vs estimate |
| Q3 2024 | Nov 12, 2024 | -$0.05-225.0% vs estimate | $547.00K-76.22% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.72-$0.26 (-3.26%)
MapLight Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.91% below the high.
$11.08+$0.01 (+0.09%)
ProMIS Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
$15.90-$1.74 (-9.86%)
Ekso Bionics Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 40.14% below the high.
$1.98+$0.01 (+0.51%)
Aytu BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.5% below the high.
$0.93+$0.05 (+5.09%)
Biofrontera Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.89% below the high.
$1.26-$0.07 (-5.26%)
American Shared Hospital Services’s quoted price sits in the lower half of its reported 52-week range, 47.28% below the high.
$1.85+$0.23 (+14.2%)
BiomX Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.5% below the high.
$0.51+$0.02 (+5.11%)
Gelteq Limited Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 74.83% below the high.
